Development of a customed designed oxygenation system combined with novel therapy to treat reperfusion injury following Neurovascular Thrombectomy.

再灌注损伤细胞功能障碍和死亡的矛盾加剧，先前缺血组织的血流恢复后，机械取栓后。血流恢复是挽救缺血组织的必要条件。然而，再灌注本身会损害心脏、肺、肾、肠、骨骼肌和脑等器官的功能/活力，甚至导致多系统器官衰竭。再灌注损伤是一个多因素的过程，导致大量危及生命的组织破坏。尽管其高发生率和相关的死亡率/发病率/卫生保健负担，但没有可用的治疗方法来减少血栓切除术后的RI。身体自身的修复机制是所有依靠从缺血状态恢复。治疗方法的使用失败了，因为血液的破坏性影响大于益处。scerefuse Medical的目标是为缺血性中风带来下一代医疗设备干预。再灌注损伤的机制对科学来说并不新鲜，但直到现在，在卒中护理中实现了足够的血运重建率，才有可能将这种改变患者生活的疗法带到患者身上。先前使用治疗方法的尝试未能减少大脑的再灌注损伤。造成这种情况的一个因素可能是在全血重新引入缺血后组织时，组织中存在有毒离子和自由基。简单地说，血液的破坏作用超过了治疗剂的好处。Cerefuse的破坏性方法旨在减少组织功能，而不依赖于药物对组织产生影响（尽管它们将被用来改变血液中的盐含量）。通过该项目，Cerefuse将*设计/组装能够成功修改血液参数的功能原型设备，*设计并实施初步动物研究，以显示最小化RI发生的安全性和有效性。*开发体外模型评估血液参数*准备监管审批策略*巩固知识产权地位

Reperfusion Injury paradoxical exacerbation of cellular dysfunction and death, post blood flow restoration to previously ischaemic tissues, post mechanical thrombectomy. Blood flow restoration is mandatory to save ischaemic tissues. However, reperfusion could compromise function/viability of range-of-organs such as heart, lung, kidney, gut, skeletal muscle and brain on their own or even cause l multi-system organ failure. Reperfusion injury is a multi-factorial process resulting in substantial life-threatening tissue destruction.Despite of its high occurrence and related mortality/morbidity/healthcare-burden, there is no treatment available to minimise RI post thrombectomy. Body's own repair mechanisms are all that is relied-upon to recover from the ischemic state. Use of therapeutics have failed as the damaging effect of the blood outweighs benefitsCerefuse Medical aims to bring about the next generation in medical device interventions for ischemic stroke. The mechanism of Reperfusion Injury isn't new to science but it is only now, with sufficient revascularisation rates achieved in stroke care that it is possible to bring this life changing therapy to patients.Previous attempts to use therapeutics have failed to reduce reperfusion injury in the brain. A contributing factor for this is likely the presence of toxic ions and free radicals in the tissue from the reintroduction of whole blood to the post ischemic tissue. In simple terms the damaging effect of the blood outweighs the benefits of the therapeutic agent.Cerefuse's disruptive approach aims to reduce tissue function without relying on pharmaceutical agents to have an effect on tissue (though they will be used to modify the salt profile of the blood).Through this project, Cerefuse will* Design/assemble functional prototype device that can successfully modify the blood parameters,* Design and implement an initial animal study to show safety and efficacy in minimising RI occurrence.* Develop _in-vitro_ models to evaluate blood parameters* Prepare regulatory-approvals-strategy* Solidify IP position